United Therapeutics Corporation

United Therapeutics Corporationverified

UTHR

Price:

$372.81

Market Cap:

$16.59B

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unit...[Read more]

Industry

Biotechnology

IPO Date

1999-06-17

Stock Exchange

NASDAQ

Ticker

UTHR

The Current Ratio as of October 2024 (TTM) for United Therapeutics Corporation (UTHR) is 4.35

According to United Therapeutics Corporation’s latest financial reports and current stock price. The company's current Current Ratio is 4.35. This represents a change of 1.21% compared to the average of 4.30 of the last 4 quarters.

United Therapeutics Corporation (UTHR) Historical Current Ratio (quarterly & annually)

How has UTHR Current Ratio performed in the past?

The mean historical Current Ratio of United Therapeutics Corporation over the last ten years is 5.14. The current 4.35 Current Ratio has changed 8.37% with respect to the historical average. Over the past ten years (40 quarters), UTHR's Current Ratio was at its highest in in the December 2022 quarter at 9.85. The Current Ratio was at its lowest in in the September 2014 quarter at 1.42.

Quarterly (TTM)
Annual

Average

5.14

Median

4.35

Minimum

1.93

Maximum

9.85

United Therapeutics Corporation (UTHR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of United Therapeutics Corporation Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 96.32%

Maximum Annual Current Ratio = 9.85

Minimum Annual Increase = -55.18%

Minimum Annual Current Ratio = 1.93

Quarterly (TTM)
Annual
YearCurrent RatioChange
20234.41-55.18%
20229.8529.45%
20217.6113.50%
20206.7066.46%
20194.03-37.00%
20186.3996.32%
20173.26-24.02%
20164.2948.12%
20152.8949.76%
20141.9346.14%

United Therapeutics Corporation (UTHR) Average Current Ratio

How has UTHR Current Ratio performed in the past?

The current Current Ratio of United Therapeutics Corporation (UTHR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

7.29

5-year avg

6.52

10-year avg

5.14

United Therapeutics Corporation (UTHR) Current Ratio vs. Peers

How is UTHR’s Current Ratio compared to its peers?

United Therapeutics Corporation’s Current Ratio is greater than Incyte Corporation (1.92), greater than Alnylam Pharmaceuticals, Inc. (3.01), greater than Ultragenyx Pharmaceutical Inc. (3.54), less than Apellis Pharmaceuticals, Inc. (5.08), less than Replimune Group, Inc. (13.46), less than Nuvalent, Inc. (17.44), less than Ventyx Biosciences, Inc. (14.19), greater than Ascendis Pharma A/S (0.74), greater than MannKind Corporation (4.07), less than Larimar Therapeutics, Inc. (10.93), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than Kiniksa Pharmaceuticals, Ltd. (3.57), greater than BeiGene, Ltd. (1.98), less than Akero Therapeutics, Inc. (24.89), greater than Blueprint Medicines Corporation (3.71), less than Vaxcyte, Inc. (17.88), less than Legend Biotech Corporation (4.84),

Build a custom stock screener for United Therapeutics Corporation (UTHR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like United Therapeutics Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

United Therapeutics Corporation (UTHR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like United Therapeutics Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is United Therapeutics Corporation's Current Ratio?

How is the Current Ratio calculated for United Therapeutics Corporation (UTHR)?

What is the highest Current Ratio for United Therapeutics Corporation (UTHR)?

What is the 3-year average Current Ratio for United Therapeutics Corporation (UTHR)?

What is the 5-year average Current Ratio for United Therapeutics Corporation (UTHR)?

How does the current Current Ratio for United Therapeutics Corporation (UTHR) compare to its historical average?